{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["19(7)"],"submitter":["Zhang C"],"pubmed_abstract":["<h4>Introduction</h4>The cystatin family is particularly relevant in lung cancer research due to its links to inflammation, protease balance, and tumor progression. Although population-based studies have documented associations between cystatin and lung cancer, causal relationships remain undetermined.<h4>Methods</h4>Based on genomic statistics of seven different cystatins and three subtypes of lung cancer, we conducted a two-sample Mendelian randomization (MR) study. The inverse-variance weighted (IVW) method was the main approach for causality estimation. The weighted median, simple mode, weighted mode, and MR-Egger regression methods were further employed to validate the main findings. In the sensitivity analysis, horizontal pleiotropy was assessed by MR-Egger regression and Cochran's Q test. MR-PRESSO and Radial MR methods were used to identify heterogeneity and remove outliers.<h4>Results</h4>Genetically predicted Cystatin 8 was causally associated with squamous cell lung carcinoma (OR = 1.062, 95% CI: 1.004-1.124, p = 0.035). No causal relationships were found for genetically predicted cystatin 8, -B, -D, -F, or -M with squamous cell lung carcinoma, lung adenocarcinoma, and NSCLC. However, outliers were identified between Cystatin D, -M, and -F using MR-PRESSO and Radial MR. After the removal of outliers, the association between Cystatin D and lung adenocarcinoma turned significant (OR = 1.178, 95% CI: 1.023-1.358, p = 0.023). Sensitivity analyses confirmed the robustness of main results after outliers removal.<h4>Conclusion</h4>Genetically predicted Cystatin 8 was causally associated with squamous cell lung carcinoma. Future population-based studies are required to substantiate these results."],"journal":["The clinical respiratory journal"],"pagination":["e70112"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12246730"],"repository":["biostudies-literature"],"pubmed_title":["Causal Associations Between Cystatin and Lung Cancer: A Two-Sample Mendelian Randomization Study."],"pmcid":["PMC12246730"],"pubmed_authors":["Liu H","Yu S","Wu R","Zhang C"],"additional_accession":[]},"is_claimable":false,"name":"Causal Associations Between Cystatin and Lung Cancer: A Two-Sample Mendelian Randomization Study.","description":"<h4>Introduction</h4>The cystatin family is particularly relevant in lung cancer research due to its links to inflammation, protease balance, and tumor progression. Although population-based studies have documented associations between cystatin and lung cancer, causal relationships remain undetermined.<h4>Methods</h4>Based on genomic statistics of seven different cystatins and three subtypes of lung cancer, we conducted a two-sample Mendelian randomization (MR) study. The inverse-variance weighted (IVW) method was the main approach for causality estimation. The weighted median, simple mode, weighted mode, and MR-Egger regression methods were further employed to validate the main findings. In the sensitivity analysis, horizontal pleiotropy was assessed by MR-Egger regression and Cochran's Q test. MR-PRESSO and Radial MR methods were used to identify heterogeneity and remove outliers.<h4>Results</h4>Genetically predicted Cystatin 8 was causally associated with squamous cell lung carcinoma (OR = 1.062, 95% CI: 1.004-1.124, p = 0.035). No causal relationships were found for genetically predicted cystatin 8, -B, -D, -F, or -M with squamous cell lung carcinoma, lung adenocarcinoma, and NSCLC. However, outliers were identified between Cystatin D, -M, and -F using MR-PRESSO and Radial MR. After the removal of outliers, the association between Cystatin D and lung adenocarcinoma turned significant (OR = 1.178, 95% CI: 1.023-1.358, p = 0.023). Sensitivity analyses confirmed the robustness of main results after outliers removal.<h4>Conclusion</h4>Genetically predicted Cystatin 8 was causally associated with squamous cell lung carcinoma. Future population-based studies are required to substantiate these results.","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-06-30T03:25:23.706Z","creation":"2026-06-30T03:21:03.659Z"},"accession":"S-EPMC12246730","cross_references":{"pubmed":["40641363"],"doi":["10.1111/crj.70112"]}}